Exane BNP Paribas Begins Coverage on Repligen (NASDAQ:RGEN)

Exane BNP Paribas began coverage on shares of Repligen (NASDAQ:RGEN) in a research note issued on Thursday, The Fly reports. The brokerage set an “outperform” rating and a $330.00 price target on the biotechnology company’s stock. Exane BNP Paribas’ price target points to a potential upside of 26.17% from the stock’s current price.

Several other research firms have also weighed in on RGEN. Stephens upped their price objective on shares of Repligen from $255.00 to $290.00 and gave the company an “overweight” rating in a research note on Friday, August 20th. BNP Paribas started coverage on shares of Repligen in a research note on Thursday. They issued an “outperform” rating and a $330.00 price objective on the stock. Zacks Investment Research lowered shares of Repligen from a “buy” rating to a “hold” rating and set a $305.00 price objective on the stock. in a research note on Tuesday, September 28th. Craig Hallum upped their price objective on shares of Repligen from $258.00 to $368.00 and gave the company a “buy” rating in a research note on Monday, September 27th. Finally, KeyCorp boosted their target price on shares of Repligen from $255.00 to $335.00 and gave the stock an “overweight” rating in a research report on Friday, September 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $306.00.

Shares of RGEN stock traded up $8.55 during trading hours on Thursday, reaching $261.56. 1,551 shares of the stock traded hands, compared to its average volume of 388,519. Repligen has a 1-year low of $162.29 and a 1-year high of $327.32. The business has a fifty day moving average price of $278.91 and a 200 day moving average price of $227.01. The firm has a market capitalization of $14.36 billion, a PE ratio of 146.31 and a beta of 0.90.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Monday, July 26th. The biotechnology company reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.52 by $0.27. The business had revenue of $162.96 million for the quarter, compared to analyst estimates of $144.24 million. Repligen had a net margin of 19.65% and a return on equity of 9.21%. The firm’s revenue was up 86.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.42 earnings per share. As a group, analysts forecast that Repligen will post 2.76 earnings per share for the current year.

In other news, Director Karen A. Dawes sold 4,585 shares of the stock in a transaction on Tuesday, July 20th. The shares were sold at an average price of $202.09, for a total value of $926,582.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Anthony Hunt sold 25,000 shares of the stock in a transaction on Thursday, September 9th. The shares were sold at an average price of $294.75, for a total transaction of $7,368,750.00. Following the completion of the transaction, the chief executive officer now owns 214,495 shares of the company’s stock, valued at approximately $63,222,401.25. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 52,154 shares of company stock valued at $14,144,680. 1.20% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the stock. RPg Family Wealth Advisory LLC acquired a new stake in shares of Repligen during the 2nd quarter worth about $27,000. Creative Financial Designs Inc. ADV grew its holdings in Repligen by 50.0% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 150 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 50 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in Repligen during the 2nd quarter worth about $37,000. Rational Advisors LLC bought a new stake in Repligen during the 2nd quarter worth about $48,000. Finally, Huntington National Bank grew its holdings in Repligen by 45.5% during the 2nd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 91 shares during the last quarter. Institutional investors and hedge funds own 83.82% of the company’s stock.

Repligen Company Profile

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

Further Reading: How to read a candlestick chart

The Fly logo

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.